Zimmer Partners’s Beam Therapeutics BEAM Stock Holding History

Zimmer Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,500	Closed	-$225K	–	112
2020 Q1	$225K	Buy	+12,500	New	+$272K	0.01%	76

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Zimmer Partners's BEAM Position: Q2 2020 in Review

Zimmer Partners sold out of Beam Therapeutics (BEAM) in Q2 2020, closing a stake of 12,500 shares — an estimated $225K sold.

Zimmer Partners first reported a position in BEAM in Q1 2020 and held it in 1 quarter. The position peaked at $225K in Q1 2020. 71 funds tracked by Wall St. Rank hold BEAM as of Q2 2020.

Zimmer Partners reported no remaining Beam Therapeutics position as of Q2 2020 after selling out during the quarter.
Zimmer Partners sold 12,500 Beam Therapeutics shares in Q2 2020, an estimated $225K.
Zimmer Partners first reported a position in Beam Therapeutics in Q1 2020 and held it in 1 quarter.
Zimmer Partners's Beam Therapeutics position peaked at $225K in Q1 2020.
71 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2020.

Based on Zimmer Partners's 13F filing for Q2 2020, filed 14 Aug 2020.